ClinicalTrials.gg
CompletedNCT01149460Updated Aug 21, 2024Results posted

Valacyclovir 1000 mg Tablet Under Fed Conditions

A Phase 1 interventional study of Valacyclovir and Valacyclovir in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study was to compare the rate and extent of absorption of Teva Pharmaceuticals USA valacyclovir and GlaxoSmithKline, USA (Valtrex) valacyclovir, administered as 1 x 1000 mg tablet under fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, non-smokers, 18 years of age and older.
  • Capable of consent

Exclusion criteria

Exclusion Criteria

Subjects to whom any of the following applies will be excluded from the study:

  • illnesses or surgery within 4 weeks of the administration of study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive testing for , or at screening.
  • abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.
  • less than 19.0 or greater than or equal to 30.0 kg/m2.
  • History of significant alcohol abuse within six months prior to the screening visit (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40% alcohol]) or positive urine drug screen at screening.
  • History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year prior to the screening visit or positive urine drug screen at screening.
  • History of allergic reactions to heparin, valacyclovir, acyclovir, or other related drugs.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, , omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to the administration of the study medication.
  • Use of an drug or participation in an investigation study within 30 days prior to the administration of the study medication.
  • Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
  • Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Difficulty to swallow study medication.
  • Use of any tobacco products in the 90 days preceding drug administration.
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical subinvestigator, could contraindicate the subjects participation in this study.
  • A depot injection or an implant of any drug within 3 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:
  • 50 mL to 300 mL of whole blood within 30 days,
  • 301 mL to 500 mL of whole blood within 45 days, or
  • more than 500 mL of whole blood within 56 days prior to drug administration.
  • Intolerance to venipunctures.
  • Clinically significant history of renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
  • Unable to understand or unwilling to sign the Form.
  • Breast-feeding.
  • Positive urine pregnancy test at screening.
  • Female subjects of having unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration. Acceptable methods of :
  • Intra-uterine contraceptive device (placed at least 4 weeks prior to study drug administration),
  • Condom or diaphragm + spermicide
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Valacyclovir

    Test 1000 mg Tablet

    Drug: Valacyclovir

  • Active comparator
    Valtrex

    Reference Listed Valacyclovir 1000 mg Tablet

    Drug: Valacyclovir

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 12 hour period

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 12 hour period

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 12 hour period

Secondary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir

    Time frame: Blood samples collected over 24 hour period

  2. AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir

    Time frame: Blood samples collected over 24 hour period

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir

    Time frame: Blood samples collected over 24 hour period

07

Results

Posted Sep 14, 2010

Participant flow

Participant flow — Overall Study
MilestoneValacyclovirValtrex®
Started1818
Completed1816
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryCmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 12 hour period
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir
ng/mLValacyclovirValtrex®
Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir385.35 ± 139.10350.86 ± 133.20
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means (t/r): 111.34 · 90% CI 100.54 to 123.29Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 12 hour period
Reported as:
Mean · ng*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir
ng*h/mLValacyclovirValtrex®
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir549.32 ± 137.87551.77 ± 140.73
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means (t/r): 100.01 · 90% CI 96.34 to 103.82Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 12 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir
ng*h/mLValacyclovirValtrex®
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir552.17 ± 138.76554.53 ± 140.97
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means (t/r): 100.01 · 90% CI 96.38 to 103.78Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.
SecondaryCmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir
Time frame:
Blood samples collected over 24 hour period
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir
ng/mLValacyclovirValtrex®
Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir6485.51 ± 1469.436283.25 ± 1375.42
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means (t/r): 103.48 · 90% CI 97.87 to 109.41Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.
SecondaryAUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir
Time frame:
Blood samples collected over 24 hour period
Reported as:
Mean · ng*h/mL
AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir
ng*h/mLValacyclovirValtrex®
AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir22514.36 ± 4316.7622675.85 ± 4063.20
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means (t/r): 99.20 · 90% CI 97.14 to 101.31Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.
SecondaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir
Time frame:
Blood samples collected over 24 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir
ng*h/mLValacyclovirValtrex®
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir22705.17 ± 4336.1622887.99 ± 4065.19
Statistical analysis
  • Valacyclovir vs Valtrex® · Ratio of least squares means: 99.10 · 90% CI 97.04 to 101.19Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valacyclovir—0/36 (0%)7/36 (19.4%)
Valtrex®—0/36 (0%)10/36 (27.8%)
Most frequent other events
Most frequent other events
EventValacyclovirValtrex®
HeadacheNervous system disorders2/364/36
Abdominal Pain/CrampGastrointestinal disorders0/364/36
Back PainMusculoskeletal and connective tissue disorders1/363/36
DizzinessNervous system disorders3/362/36
Loose/Soft StoolsGastrointestinal disorders1/362/36
NauseaGastrointestinal disorders0/362/36
Low Hemoglobin LevelBlood and lymphatic system disorders2/361/36
Fatigue/DrowsinessGeneral disorders0/362/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ValacyclovirValtrex®Total
<=18 years000
Between 18 and 65 years181735
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)ValacyclovirValtrex®Total
Female71017
Male11819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ValacyclovirValtrex®Total
Caucasian181836
Region of Enrollment
Region of Enrollment(participants)ValacyclovirValtrex®Total
Canada181836
08

Study locations

1 site
  • Anapharm Inc.
    Sainte-Foy, Quebec G1V 2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Sep 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2010
First posted
Jun 23, 2010
Start
Sep 2004
Primary completionActual
Sep 2004
CompletionActual
Sep 2004
Results first posted
Sep 14, 2010
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01149460
First posted
Jun 23, 2010
Start date
Sep 2004
Primary completion
Sep 2004
Completion
Sep 2004
Results posted
Sep 14, 2010
Last update
Aug 21, 2024

Study contacts

Benoit Girard, MD
principal investigator · Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion